In Germany, hospitals spent €20B on medical materials in 2023:
▪️ 37% on pharma
▪️ 19% on implants
▪️ 16% on consumables

Costs grew 50% in 10 years — even though case numbers declined.

Everyone points to wages, energy, or logistics. But IMF data shows:
👉 Almost half of price increases came from corporate profits, not real costs.

That’s why MedTech pricing is so complex:
• A DES stent can cost 2–6x more in the US than in Germany.
• Price is not just “inflation” — it’s market power.

For distributors in Africa, LATAM, and Asia this means:
⚠️ If you don’t know why a quote is high, you can’t protect your margin in tenders.

This is where procurement shifts from “buying” → to “reading the system”.

We help partners:
▪️ Spot unjustified price hikes
▪️ Secure alternative sourcing
▪️ Keep their tenders competitive even in volatile markets

Because the real cost driver isn’t always materials.
Sometimes it’s the strategy of the supplier.